Related Experiment Video

Updated: Apr 11, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

140

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment

Xiaoqi Liu1

  • 1Purdue University, West Lafayette, IN, USA.

Translational Oncology
|June 10, 2015
PubMed

Insights

Polo-like kinases (Plks) regulate cell division and are crucial in cancer development. This review covers Plk roles and inhibitors being developed as cancer therapies.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Polo-like kinases (Plks) are serine-threonine kinases regulating key cellular processes.
  • Plk1, a prominent member, is vital for mitosis and frequently overexpressed in various cancers.

Purpose of the Study:

  • To review the biological functions of Plks in cell cycle progression and cancer.
  • To discuss the mechanisms of action for Plk inhibitors in cancer therapy development.

Main Methods:

  • Literature review of biological roles of Plks.
  • Analysis of mechanisms of action of Plk inhibitors in clinical development.

Main Results:

  • Plks are essential regulators of DNA replication and mitosis.
  • Overexpression of Plk1 is a hallmark of many cancers, making it a therapeutic target.
  • Several Plk inhibitors are in various stages of clinical trials for hematological malignancies and other cancers.

Conclusions:

  • Plk inhibitors demonstrate therapeutic potential in cancer treatment.
  • Targeting Plks offers a promising strategy for novel cancer therapies.

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.8K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K